Tekmira’s Partner Presents New Clinical Data for LNP-Enabled Patisiran (ALN-TTR02)

Tekmira’s Partner Presents New Clinical Data for LNP-Enabled Patisiran (ALN-TTR02)

[GlobeNewswire] – VANCOUVER, British Columbia — Tekmira Pharmaceuticals Corporation , a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented new clinical … more

View todays social media effects on TKMR

View the latest stocks trending across Twitter. Click to view dashboard

See who Tekmira is hiring next, click here to view

Share this post

Comments (0)